Exercise of Warrants and Total Voting Rights

RNS Number : 7352U
Belluscura PLC
07 December 2021
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura PLC

("Belluscura" or the "Company" or "Group")

Exercise of Warrants and Total Voting Rights

 

Director / PDMR Shareholding

 

 

LONDON, U.K. AND PLANO, TX, U.S. (7 December 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from staff warrant holders to exercise warrants over 348,506 shares in the share capital of Belluscura ("the Warrant Shares") at exercise prices of 13 pence (308,506 shares) and 15 pence (40,000 shares). The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £46,555.72.

 

The Company was notified that on 6 December 2021 Chief Executive Officer Robert Rauker exercised 179,537 Warrant Shares at an average price of 13.45 pence per share. Mr Rauker now holds 955,684 shares and his total interest in the Company has increased to 0.84% of the Company's enlarged issued share capital. 

 

The Company was also notified that on 6 December 2021 Chief Financial Officer Tony Dyer exercised 141,404 Warrant Shares at a price of 13.00 pence per share. Mr Dyer now holds 778,345 shares and his total interest in the Company has increased to 0.68% of the Company's enlarged issued share capital. 

 

The Warrant Shares were allotted on 6 December 2021. Application has been made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or around 10 December 2021. These shares will rank pari passu with the ordinary shares of the Company in issue.

 

Total voting rights

 

The Company's total issued capital, after the issue of the Warrant Shares, will be 113,835,444 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

 

For further information please contact:

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via Walbrook PR

Anthony Dyer, Chief Financial Officer

 

 

 

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

 

 

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated


a)

Name

Anthony Dyer




2

Reason for notification

 

a)

Position / status

Chief Financial Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument
Identification code

Ordinary shares of £0.01 each in Belluscura plc
ISIN : 
GB00BD3B8Z11

b)

Nature of the transaction

Exercise of Warrants

c)

 

 

 

 

Price(s) and volumes(s)

 

 

 

 

Price

 

£0.13

Volume

 

141,404

d)

Aggregated information

n/a

e)

Date of the transaction

6 December 2021

f)

Place of the transaction

Outside a trading venue

 



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated


a)

Name

Robert Rauker




2

Reason for notification

 

a)

Position / status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument
Identification code

Ordinary shares of £0.01 each in Belluscura plc
ISIN : 
GB00BD3B8Z11

b)

Nature of the transaction

Exercise of Warrants

c)

 

 

 

 

Price(s) and volumes(s)

 

 

 

 

Price

£0.13

£0.15

Volume

40,000

139,537

d)

Aggregated information

n/a

e)

Date of the transaction

6 December 2021

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPGBAPUPGGQQ

Companies

Belluscura (BELL)
UK 100

Latest directors dealings